Redirecting to original paper in 30 seconds...
Click below to go immediately or wait for automatic redirect
📄 Abstract
Abstract: Purpose: Medical foundation models (FMs) offer a path to build
high-performance diagnostic systems. However, their application to prostate
cancer (PCa) detection from micro-ultrasound ({\mu}US) remains untested in
clinical settings. We present ProstNFound+, an adaptation of FMs for PCa
detection from {\mu}US, along with its first prospective validation. Methods:
ProstNFound+ incorporates a medical FM, adapter tuning, and a custom prompt
encoder that embeds PCa-specific clinical biomarkers. The model generates a
cancer heatmap and a risk score for clinically significant PCa. Following
training on multi-center retrospective data, the model is prospectively
evaluated on data acquired five years later from a new clinical site. Model
predictions are benchmarked against standard clinical scoring protocols
(PRI-MUS and PI-RADS). Results: ProstNFound+ shows strong generalization to the
prospective data, with no performance degradation compared to retrospective
evaluation. It aligns closely with clinical scores and produces interpretable
heatmaps consistent with biopsy-confirmed lesions. Conclusion: The results
highlight its potential for clinical deployment, offering a scalable and
interpretable alternative to expert-driven protocols.
Authors (10)
Paul F. R. Wilson
Mohamed Harmanani
Minh Nguyen Nhat To
Amoon Jamzad
Tarek Elghareb
Zhuoxin Guo
+4 more
Submitted
October 30, 2025
Key Contributions
ProstNFound+ adapts medical foundation models for prostate cancer detection using micro-ultrasound, incorporating a custom prompt encoder for clinical biomarkers. It demonstrates strong generalization in its first prospective clinical validation, showing no performance degradation compared to retrospective evaluation and benchmarking against standard clinical protocols.
Business Value
Offers a potentially more accurate and efficient method for prostate cancer detection, improving patient outcomes and potentially reducing healthcare costs associated with late-stage diagnosis or unnecessary biopsies.